Mairus McFarland, MD
Family Medicine · Shreveport, LANPI 1114945656
Payments from drug & device makers
Across 427 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$1K
- Johnson & Johnson$401
- Otsuka America Pharmaceutical, Inc.$375
- Phathom Pharmaceuticals, Inc.$349
- Novartis$326
- plus $2K from 21 others
What the payments were for
- Food & beverage$6,73398%
- Education$1332%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 95 | $1,837 |
| Novo Nordisk | 98 | $1,166 |
| Johnson & Johnson | 34 | $401 |
| Otsuka America Pharmaceutical, Inc. | 23 | $375 |
| Phathom Pharmaceuticals, Inc. | 16 | $349 |
| Novartis | 23 | $326 |
| Teva Pharmaceuticals USA, Inc. | 15 | $306 |
| Lundbeck LLC | 16 | $275 |
| Sanofi-aventis U.S. LLC | 19 | $270 |
| Kowa Pharmaceuticals America, Inc. | 17 | $252 |
| Astellas Pharma US Inc | 15 | $228 |
| Sumitomo Pharma America, Inc. | 10 | $226 |
| Merck | 9 | $135 |
| Smith+Nephew | 1 | $124 |
| Pfizer | 10 | $121 |
| Neurocrine Biosciences, Inc. | 5 | $111 |
| Acadia Pharmaceuticals Inc | 4 | $70 |
| Ardelyx, Inc. | 4 | $64 |
| Avanir Pharmaceuticals, Inc. | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| AbbVie | 2 | $32 |
| Amgen | 2 | $26 |
| Neurelis, Inc. | 1 | $22 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Boston Scientific | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| GSK | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,866 in reported general payments places this provider in the 85th percentile of 1,469 family medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 633 | $197,451 |
| Invega SustennaPaliperidone Palmitate | 42 | $150,891 |
| XareltoRivaroxaban | 208 | $97,235 |
| LinzessLinaclotide | 111 | $86,751 |
| IngrezzaValbenazine Tosylate | 20 | $85,705 |
| MyrbetriqMirabegron | 136 | $61,775 |
| JardianceEmpagliflozin | 174 | $61,687 |
| FarxigaDapagliflozin Propanediol | 95 | $56,266 |
| RexultiBrexpiprazole | 72 | $55,064 |
| EntrestoSacubitril/Valsartan | 118 | $46,456 |
| MounjaroTirzepatide | 37 | $42,438 |
| OzempicSemaglutide | 41 | $39,170 |
| TrulicityDulaglutide | 53 | $38,997 |
| VraylarCariprazine Hcl | 54 | $38,570 |
| Abiraterone Acetate | 20 | $35,994 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Xarelto | $401 | $248,126250 claims |
| PfizerEliquis | $121 | $197,451633 claims |
| AbbVieLinzess, Vraylar | $32 | $125,321165 claims |
| AstraZenecaFarxiga, Lokelma, Breztri Aerosphere | $1,837 | $89,743166 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $111 | $85,70520 claims |
| Astellas Pharma US IncMyrbetriq | $228 | $61,775136 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $375 | $55,06472 claims |
| NovartisEntresto | $326 | $46,456118 claims |
| Novo NordiskOzempic | $1,166 | $39,17041 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $37 | $32,74342 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $14 | $24,71738 claims |
| MerckJanuvia, Janumet | $135 | $24,52657 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,469 family medicine providers in Louisiana.
Other family medicine in Shreveport
- Michael FlemingShreveport$165K
- David NelsonShreveport$59K
- Krishna SinghShreveport$22K
- Larry FlakeShreveport$20K
- Russell CarrShreveport$17K
- Richard KammShreveport$17K
- Wendy MosesShreveport$16K
- Clinton GuilloryMonroe$18.5M
- Jason MorrisLake Charles$18M
- Michael SeepLake Charles$9.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.